**Table S1.** Baseline clinical features in entire study cohort and the three subgroups identified according to professional risk exposure.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Entire study cohort****(n = 381)** | **Healthcare staff****(n = 185)** | **High public exposure****(n = 31)** | **Low public exposure****(n = 165)** | ***p* value** |
| **Demographic and clinical features** |  |  |  |
| Age (years) | 35.0 ± 11.7 | 32.6 ± 8.3 | 38.7 ± 12.5 | 37.1 ± 14.2 | **<0.001** |
| Male gender, n (%) | 126 (33.1) | 58 (31.4) | 13 (41.9) | 55 (33.3) | 0.508 |
| Female gender, n (%) | 255 (66.9) | 127 (68.6) | 18 (58.1) | 110 (66.7) | 0.508 |
| Previous or current smoker, n (%) | 122 (32) | 57 (67) | 9 (29.1) | 56 (33.9) | 0.934 |
| **Comorbidities, n (%)** |  |  |  |  |  |
| Panic Attack | 13 (3.4) | 5 (2.7) | 0 (0) | 8 (4.8) | 0.300 |
| Asthma | 16 (4.2) | 7 (3.8) |  1 (3.2) | 8 (4.8) | 0.850 |
| Nose and Sinus Disorders | 12 (3.1) | 7 (3.8) |  1 (3.2) | 4 (2.4) | 0.768 |
| Mood Disorders | 16 (4.2) | 5 (2.7) |  0 (0.0) | 11 (6.7) | 0.087 |
| Skin Diseases | 7 (1.8) | 3 (1.6) | 0 (0.0) | 4 (2.4) | 0.624 |
| Autoimmune Diseases | 16 (4.2) | 5 (1.3) | 0 (0.0) | 11 (6.7) | 0.087 |
| Seasonal Allergies | 137 (36.0) | 65 (35.1) | 8 (25.8) | 64 (38.8) | 0.365 |
| Round-year Allergies | 74 (19.4) | 39 (21.1) | 5 (16.1) | 30 (18.2) | 0.704 |
| Use of Glasses | 188 (49.3) | 96 (51.9) | 15 (48.4) | 77 (46.7) | 0.897 |
| Use of contact lenses | 52 (13.6) | 25 (6.6) | 4 (1.0) | 23 (6.0) | 0.897 |

Data are presented as n (%), mean ± SD or median [IQR].

**Table S2.** Type of PPE used and wearing time, per day and per week, in entire study cohort and the three subgroups identified according to professional risk exposure.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Entire study cohort****(n = 381)** | **Healthcare staff****(n = 185)** | **High public exposure****(n = 31)** | **Low public exposure****(n = 165)** | ***p* value** |
| **PPE, n (%)** |  |  |  |  |  |
| Surgical mask | 276 (72.4) | 154 (83.2) | 18 (58.1) | 104 (63.0) | **<0.001** |
| Cotton mask | 73 (19.2) | 13 (7.0) | 7 (22.6) | 53 (32.1) | **<0.001** |
| Respirator masks (N95) |  |  |  |  |  |
| Foldable FFP2/3 without filter | 138 (36.2) | 88 (47.6) | 8 (25.8) | 42 (25.5) | **<0.001** |
| Foldable FFP2/3 with filter | 48 (12.6) | 26 (14.1) | 2 (6.5) | 20 (12.1) | 0.483 |
| Cup FFP2/3 without filter | 40 (10.5) | 26 (14.1) | 3 (9.7) | 11 (6.7) | 0.078 |
| Cup FFP2/3 with filter |  39 (10.2) | 19 (10.3) | 3 (9.7) | 17 (10.3) | 0.994 |
| Combination Surgical + FFP2/3 | 56 (14.7) | 54 (29.2) | 0 (0.0) | 2 (1.2) | **<0.001** |
| Cap  | 89 (23.4) | 88 (47.6) | 1 (3.2) | 0 (0.0) | **<0.001** |
| Googles | 74 (19.4) | 68 (36.8) | 1 (3.2) | 5 (3.0) | **<0.001** |
| Face shield  | 47 (12.3) | 47 (25.4) | 0 (0.0) | 0 (0.0) | **<0.001** |
| **Wearing time, Days / week, n (%)** |  |  |  |  |  |
| 1 day / week | 72 (18.9) | 11 (5.9) | 3 (9.7) | 58 (35.2) | **<0.001** |
| 2 days / week | 52 (13.6) | 8 (4.3) | 6 (19.4) | 38 (23.0) | **<0.001** |
| 3-6 days / week | 143 (37.5) | 97 (52.4) | 12 (38.7) | 34 (20.6) | **<0.001** |
| 7 days / week | 103 (27.0) | 69 (37.3) | 10 (32.3) | 24 (14.5) | **<0.001** |
| **Wearing time, Hours / day, n (%)** |  |  |  |  |  |
| < 1 hour / day | 69 (18.1) | 8 (4.3) | 6 (19.4) | 55 (33.3) | **<0.001** |
| 1-2 hours / day | 76 (19.9) | 9 (4.9) | 7 (22.6) | 60 (36.4) | **<0.001** |
| 3-6 hours / day | 56 (14.7) | 31 (16.8) | 10 (32.3) | 15 (9.1) | **<0.001** |
| 6-12 hours / day | 135 (35.4) | 114 (61.6) | 7 (22.6) | 14 (8.5) | **<0.001** |
| > 12 hours / day | 24 (6.3) | 22 (11.9) | 1 (3.2) | 1 (0.6) | **<0.001** |

**Table S3.** PPE-related symptoms according to weekly wearing time in the entire study cohort.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **entire study cohort****(n = 381)** | **< 3 days/week****(n = 124)** | **>= 3 days/week****(n = 246)** | ***p* value** |
| **Symptoms, n (%)** |  |  |  |  |
| **Nasal symptoms** | 306 (80.3) | 87 (70.2) | 216 (87.8) | **<0.001** |
| Nasal obstruction / dyspnea | 248 (65.1) | 71 (57.3) | 174 (70.7) | **0.001** |
| Dry nose / Crusting | 161 (42.3) | 27 (21.8) | 133 (54.1) | **<0.001** |
| Sneezing / Runny nose | 152 (39.9) | 39 (31.5) | 112 (45.5) | **0.004** |
| Itchy nose | 200 (52.5) | 52 (41.9) | 147 (59.8) | **<0.001** |
| **Skin symptoms**  | 202 (53.0) | 52 (41.9) | 149 (60.6) | **<0.001** |
| Skin Itching | 156 (40.9) | 46 (37.1) | 110 (44.7) | **0.007** |
| Skin Rash / Dermatitis | 77 (20.2) | 12 (9.7) | 64 (26.0) | **0.001** |
| Acne / Increased pore size | 105 (27.6) | 18 (14.5) | 87 (35.4) | **<0.001** |
| **Decubitus related Symptoms** | 261 (68.5) | 62 (50.0) | 196 (79.7) | **<0.001** |
| Nasal / facial Pain | 155 (40.7) | 37 (29.8) | 116 (47.2) | **0.002** |
| Redness zygoma / forehead | 158 (41.5) | 30 (24.2) | 125 850.8) | **<0.001** |
| Decubitus lesions at zygoma / forehead | 54 (14.2) | 7 (5.6) | 47 (19.1) | **0.001** |
| Redness Nosebridge | 180 (47.2) | 43 (34.7) | 135 (54.9) | **<0.001** |
| Decubitus lesions at nosebridge | 50 (13.1) | 6 (4.8) | 44 (17.9) | **0.001** |
| Dysmorfic nose | 46 (12.1) | 10 (8.1) | 35 (14.2) | 0.218 |
| Auricolar pain | 166 (43.6) | 30 (24.2) | 136 (55.3) | **<0.001** |
| **Ocular Symptoms** | 133 (34.9) | 33 (26.6) | 98 (39.8) | **0.021** |
| **Head itch**  | 106 (27.8) | 21 (16.9) | 85 (34.6) | **<0.001** |
| **Worsening of Allergy** | 53 (13.9) | 11 (8.9) | 42 (17.1) | **0.040** |
| **Mood Deflection** | 135 (35.4) | 36 (29.0) | 98 (39.8) | **0.022** |
| **Panic Attack** | 37 (9.7) | 13 (10.5) | 24 (9.8) | 0.530 |

**Table S4.** PPE-related symptoms and resolution time after removal according to daily wearing time in the entire study cohort.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **entire study cohort****(n = 381)** | **< 6 hours/day****(n = 201)** | **>= 6 hours/day****(n = 159)** | ***p* value** |
| **Symptoms, n (%)** |  |  |  |  |
| **Nasal symptoms** | 306 (80.3) | 150 (74.6) | 148 (93.1) | **<0.001** |
| Nasal obstruction / dyspnea | 248 (65.1) | 121 (60.2) | 119 (74.8) | **<0.001** |
| Dry nose / Crusting | 161 (42.3) | 58 (28.9) | 100 (62.9) | **<0.001** |
| Sneezing / Runny nose | 152 (39.9) | 66 (32.8) | 83 (52.2) | **<0.001** |
| Itchy nose | 200 (52.5) | 93 (46.3) | 103 (64.8) | **<0.001** |
| **Skin symptoms**  | 202 (53.0) | 91 (45.3) | 107 (67.3) | **<0.001** |
| Skin Itching | 156 (40.9) | 77 (38.3) | 76 (47.8) | **0.007** |
| Skin Rash / Dermatitis | 77 (20.2) | 25 (12.4) | 51 (32.1) | **<0.001** |
| Acne / Increased pore size | 105 (27.6) | 32 (15.9) | 72 (45.3) | **<0.001** |
| **Decubitus related Symptoms** | 261 (68.5) | 115 (57.2) | 142 (89.3) | **<0.001** |
| Nasal / facial Pain | 155 (40.7) | 65 (32.3) | 88 (55.3) | **<0.001** |
| Redness zygoma / forehead | 158 (41.5) | 61 (30.3) | 94 (59.1) | **<0.001** |
| Decubitus lesions at zygoma / forehead | 54 (14.2) | 21 (10.4) | 33 (20.8) | **0.003** |
| Redness Nosebridge | 180 (47.2) | 78 (38.8) | 99 (62.3) | **<0.001** |
| Decubitus lesions at nosebridge | 50 (13.1) | 17 (8.5) | 33 (20.8) | **<0.001** |
| Dysmorfic nose | 46 (12.1) | 18 (9.0) | 27 (17.0) | **0.039** |
| Auricolar pain | 166 (43.6) | 58 (28.9) | 108 (67.9) | **<0.001** |
| **Ocular Symptoms** | 133 (34.9) | 56 (27.9) | 72 (45.3) | **0.001** |
| **Head itch**  | 106 (27.8) | 45 (22.4) | 60 (37.7) | **<0.001** |
| **Worsening of Allergy** | 53 (13.9) | 21 (10.4) | 31 (19.5) | **0.022** |
| **Mood Deflection** | 135 (35.4) | 69 (34.3) | 63 (39.6) | **0.066** |
| **Panic Attack** | 37 (9.7) | 23 (11.4) | 13 (8.2) | 0.427 |

**Table S5.** PPE-related symptoms and resolution time after removal according to type of respirator mask used in the Healthcare staff.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Healthcare cohort(n = 185) | Surgical mask(n = 61) | FFP2/3 mask(n = 124) | *p* value |
| Symptoms, n (%) |  |  |  |  |
| Nasal symptoms | 168 (90.8) | 54 (88.5) | 114 (91.9) | 0.450 |
| * Nasal obstruction / dyspnea
 | 136 (73.5) | 47 (77.0) | 89 (71.8) | 0.445 |
| * Dry nose / Crusting
 | 108 (58.4) | 32 (52.5) | 76 (61.3) | 0.252 |
| * Sneezing / Runny nose
 | 92 (49.7) | 25 (41.0) | 67 (54.0) | 0.095 |
| * Itchy nose
 | 118 (63.8) | 36 (59.0) | 82 (66.1) | 0.344 |
| Skin symptoms  | 121 (65.4) | 38 (62.3) | 83 (66.9) | 0.533 |
| * Skin Itching
 | 86 (46.5) | 24 (39.3) | 62 (50.0) | 0.172 |
| * Skin Rash / Dermatitis
 | 54 (29.2) | 12 (19.7) | 42 (33.9) | 0.046 |
| * Acne / Increased pore size
 | 79 (42.7) | 25 (41.0) | 54 (43.5) | 0.740 |
| Decubitus related Symptoms | 158 (85.4) | 46 (75.4) | 112 (90.3) | **0.007** |
| * Nasal / facial Pain
 | 93 (50.3) | 14 (23.0) | 79 (63.7) | **<0.001** |
| * Redness zygoma / forehead
 | 101 (54.6) | 25 (41.0) | 76 (61.3) | **0.009** |
| * Decubitus lesions at zygoma / forehead
 | 36 (19.5) | 5 (8.2) | 31 (86.1) | **0.007** |
| * Redness Nosebridge
 | 114 (61.6) | 19 (31.1) | 29 (76.6) | **<0.001** |
| * Decubitus lesions at nosebridge
 | 39 (21.1) | 4 (6.6) | 35 (28.2) | **0.001** |
| * Dysmorfic nose
 | 26 (14.1) | 2 (3.3) | 24 (19.4) | **0.003** |
| * Auricolar pain
 | 121 (65.4) | 36 (59.0) | 85 (68.5) | 0.200 |
| Ocular Symptoms | 83 (44.9) | 28 (45.9) | 55 (44.4) | 0.842 |
| Worsening of Allergy | 36 (19.5) | 8 (13.1) | 28 (22.6) | 0.126 |
| Mood Deflection | 75 (40.5) | 21 (34.4) | 54 (43.5) | 0.235 |
| Panic Attack | 17 (9.2) | 2 (3.3) | 15 (12.1) | 0.051 |

Data are presented as n (%) or mean ± SD.

**Table S6.** PPE-related symptoms according to use of googles or Face shields in the Healthcare staff.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Healthcare cohort(n = 185) | Googles/Face shieldsvisor(n = 87) | No visor*(n = 98)* | *p* value |
| Symptoms, n (%) |  |  |  |  |
| Nasal / facial Pain | 93 (50.3) | 56 (64.4) | 37 (37.8) | **<0.001** |
| Redness zygoma / forehead | 101 (54.6) | 58 (66.7) | 43 (43.9) | **0.002** |
| Decubitus lesions at zygoma / forehead | 36 (19.5) | 22 (25.3) | 14 (14.3) | 0.059 |
| Redness Nosebridge | 114 (61.6) | 64 (73.6) | 50 (51.0) | **0.002** |
| Decubitus lesions at nosebridge | 39 (21.1) | 23 (26.4) | 16 (16.3) | 0.092 |
| Dysmorfic nose | 26 (14.1) | 16 (18.4) | 10 (10.2) | 0.110 |
| Auricolar pain | 121 (65.4) | 64 (73.6) | 57 (58.2) | **0.028** |
| Ocular Symptoms | 83 (44.9) | 40 (46.0) | 43 (43.9) | 0.774 |

**Table S7.** PPE-related symptoms according to use of cap in the Healthcare staff.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Healthcare cohort(n = 185) | No cap(n = 97) | *cap**(n = 88)* | *p* value |
| Symptoms, n (%) |  |  |  |  |
| Decubitus related Symptoms |  |  |  |  |
| * Nasal / facial Pain
 | 93 (50.3) | 40 841.2) | **53 (60.2)** | **0.010** |
| * Redness zygoma / forehead
 | 101 (54.6) | 44 (45.4) | **57 (64.8)** | **0.008** |
| * Decubitus lesions at zygoma / forehead
 | 36 (19.5) | 15 (15.5) | 21 (23.9) | 0.150 |
| * Dysmorfic nose
 | 26 (14.1) | 12 (12.4) | 14 (15.9) | 0.489 |
| * Auricolar pain
 | 121 (65.4) | 55 (56.7) | **66 (75.0)** | **0.009** |
| Head itch  | 73 (39.5) | 24 (24.7) | 49 (55.7) | **<0.001** |